Team
health

BED Calculator

Radiotherapy planning requires precise quantification of dose effects across different tissue types. This calculator computes biologically effective dose (BED) and equivalent dose in 2-Gy fractions (EQD₂) based on fractionation schedules, tissue sensitivity, and dose-rate repair kinetics. Oncologists and radiation physicists use these metrics to compare treatment protocols, predict late toxicity, and optimise dose escalation across varied clinical scenarios.

Last updated:

Creators Adena Benn, BSc
7,615 people find this calculator helpful

How to Use This Calculator

To calculate BED and EQD₂, gather three key pieces of information:

  • Irradiation duration: Specify whether each fraction is delivered in less than a few minutes (acute exposure) or over a prolonged period (slow dose rate). Prolonged delivery allows intracellular repair mechanisms to reduce net biological damage.
  • α/β ratio: This tissue-specific parameter quantifies radiosensitivity. Early-reacting tissues (skin, mucosa, lens) typically have α/β ≈ 10 Gy. Late-reacting tissues (spinal cord, kidney, fibrosis-prone structures) have α/β ≈ 3 Gy. Tumours vary from 5–20 Gy depending on histology.
  • Dose parameters: Enter dose per fraction and total dose, or let the calculator derive one from the other.

For protracted treatments (brachytherapy, hypofractionated schedules), the dose-rate factor (g-factor, <1) accounts for repair kinetics during treatment.

BED and EQD₂ Formulas

Two equations govern dose biologically effective calculations. The standard BED formula applies to acute delivery. When dose is protracted, a repair factor modulates the second term.

BED = D × (1 + d / (α/β))

BEDprotracted = D × (1 + g × d / (α/β))

EQD₂ = D × [(d + α/β) / (2 + α/β)]

  • D — Total absorbed dose (Gy)
  • d — Dose per fraction (Gy)
  • α/β — Tissue-specific radiosensitivity ratio (Gy); lower values indicate late-reacting tissues
  • g — Dose-rate factor for protracted delivery (0 to 1); accounts for intracellular repair

Clinical Interpretation of BED and EQD₂

BED quantifies the total biological damage regardless of fractionation pattern. A schedule with low dose-per-fraction but high total dose may achieve the same BED as hypofractionated delivery, yet produce fewer acute side-effects. This principle underpins modern dose-escalation trials.

EQD₂ translates any fractionation scheme into an equivalent dose delivered in conventional 2-Gy fractions—a reference standard in clinical oncology. A protracted course with 1.8 Gy × 30 fractions yields lower EQD₂ (and fewer late effects) than 2.5 Gy × 20 fractions, even if total dose is identical. Radiation physicists use EQD₂ to compare historical series and predict normal-tissue toxicity thresholds.

Critical Assumptions and Pitfalls

BED calculations rely on the linear-quadratic model and tissue-specific α/β values; real biology introduces individual and spatial heterogeneity.

  1. α/β ratios are population estimates — Published α/β values derive from clinical outcome data and vary between patients and tumour subtypes. Individual variation in repair capacity can shift effective α/β by ±2–3 Gy. Always treat BED as a comparative metric, not an absolute predictor.
  2. Dose inhomogeneity is not captured — BED assumes uniform dose to the organ or volume of interest. In reality, dose escalation to high-risk regions and dose-painting strategies create subvolumes with different fractionation patterns. Spatially heterogeneous schedules cannot be reduced to a single BED value.
  3. Repair assumptions break down at extreme dose rates — The dose-rate factor g was derived from radiobiology experiments at specific dose rates. Ultra-high dose-rate regimens (FLASH, >40 Gy/s) may violate the linear-quadratic framework and produce unexpected normal-tissue sparing.
  4. Late toxicity thresholds are organ-specific — A spinal cord EQD₂ exceeding 50 Gy carries substantial myelopathy risk, yet the same EQD₂ to rectum may be acceptable. Always cross-check BED against organ-specific tolerance curves and clinical guidelines, not BED values alone.

Fractionation Schedules and Biologically Effective Dose

Standard fractionation (1.8–2.0 Gy daily, 5 days/week) remains the clinical baseline for dose-response and toxicity prediction. Hypofractionated schedules (e.g. 3–10 Gy per fraction) compress treatment into fewer weeks but require careful α/β selection—tumours tolerate hypofractionation better than late-reacting normal tissues. Accelerated schedules (same total dose in fewer days) reduce time for repopulation in fast-dividing tumour cells but increase acute toxicity.

Particle therapy (proton, carbon) typically uses the same BED model but benefit from reduced dose to surrounding tissue. Brachytherapy and IMRT with multiple small beams deliver non-uniform dose, complicating BED interpretation; volumetric averaging or substructure analysis may be required for accurate prediction.

Frequently Asked Questions

What is the difference between BED and EQD₂?

BED quantifies the total biological damage to a tissue based on dose, fractionation, and tissue sensitivity (α/β). EQD₂ converts that biological damage into an equivalent dose delivered in conventional 2-Gy fractions. Both use the same underlying biology but serve different purposes: BED compares any two schedules directly, while EQD₂ benchmarks against historical clinical experience with 2-Gy fractions. For example, 60 Gy in 30 fractions (2 Gy each) has BED and EQD₂ that differ numerically depending on α/β.

How do I choose the correct α/β ratio for my treatment site?

α/β values are tissue and outcome dependent. Early-reacting tissues (acute toxicity) use α/β ≈ 10 Gy; late-reacting tissues (fibrosis, necrosis) use α/β ≈ 3 Gy. Tumours range from 5–20 Gy depending on histology and radiosensitivity. Consult published radiobiology reviews (e.g. from radiotherapy societies) or treatment guidelines for your specific organ and endpoint. When in doubt, calculate BED using multiple α/β values to explore sensitivity.

What happens if I use a dose rate factor (g-factor) less than 1?

A g-factor less than 1 indicates protracted or low-dose-rate delivery, allowing cells time to repair damage between exposure periods. This reduces BED compared to acute delivery at the same total and fractional doses. Brachytherapy, overnight continuous infusion, and some external-beam modalities qualify. Lower g-factors (0.3–0.7) reflect slower repair or longer treatment intervals. Always verify the g-factor from your radiation physics team; incorrect values significantly under- or overestimate biological effect.

Can BED predict individual patient toxicity?

BED provides a population-level estimate of toxicity risk based on fractionation, dose, and tissue type. Individual variation in radiosensitivity (genetic, comorbidities, concurrent chemotherapy) can shift actual tolerance by 10–20% or more. BED should inform treatment planning but never replace clinical judgment. Patients with severe acute reactions or pre-existing organ dysfunction may tolerate lower EQD₂ than the population average. Always review BED estimates with your multidisciplinary team before final plan approval.

Why do some radiotherapy protocols use 2.5 Gy or 3 Gy fractions instead of 2 Gy?

Higher fractional doses shorten treatment time and reduce tumour repopulation, beneficial for aggressive or radioresistant cancers. However, late normal-tissue toxicity increases disproportionately because late-reacting tissues have low α/β (≈3 Gy), making them sensitive to large fraction sizes. A 2.5-Gy fraction delivers higher BED and EQD₂ per session, necessitating lower total dose to keep late toxicity acceptable. This trade-off—shorter treatment, higher per-fraction dose, lower total dose—suits certain tumours (prostate, lung SBRT) but is avoided where late effects must be minimised.

How do I interpret BED values in Gy?

BED is expressed in Gray-equivalent units and reflects cumulative biological damage. Two schedules with the same BED should produce similar biological outcomes (tumour control or toxicity) despite different fractionation patterns. For example, 30 Gy in 10 × 3-Gy fractions and 60 Gy in 30 × 2-Gy fractions might yield the same BED to a late-reacting tissue (α/β = 3), meaning equivalent late toxicity risk. BED values are only meaningful when compared using the same α/β; always state the tissue and α/β value when reporting BED numbers.

More health calculators (see all)

NAFLD Fibrosis Score Calculator Adderall Dosage Calculator Vaccine Queue Scotland Calculator Absolute Reticulocyte Count Calculator Endotracheal Tube Size Calculator Arterial Age Calculator Calorie Deficit Calculator Diet Risk Score Calculator